- Pharmacology
- Allergy, Immunology, and ENT
- Cardiology
- Emergency Medicine
- Endocrinology
- Adolescent Medicine
- Gastroenterology
- Infectious Diseases
- Neurology
- OB/GYN
- Practice Improvement
- Gynecology
- Respiratory
- Dermatology
- Mental, Behavioral and Development Health
- Oncology
- Rheumatology
- Sexual Health
- Pain
Vaccines approved for invasive pneumococcal disease and meningococcal disease
Pfizer's pneumococcal 13-variant conjugate vaccine (Prevnar 13) was approved by the FDA for active immunization of children aged 6 weeks through 5 years for the prevention of invasive disease caused by 13 Streptococcus pneumoniae serotypes.
Pfizer's pneumococcal 13-valent conjugate vaccine (diphtheria CRM197 protein) (Prevnar 13) was approved by the FDA for active immunization of children aged 6 weeks through 5 years for the prevention of invasive disease caused by 13 Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F. The vaccine was also approved for the prevention of otitis media caused by serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F.
Novartis received approval from the FDA for a meningococcal (groups A, C, Y, and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine (Menveo) for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitides serogroups A, C, Y, and W-135 in patients aged 11 to 55 years.
The benefits of concurrent fetal and maternal heart rate monitoring
April 17th 2024A recent study revealed that employing maternal heart rate monitoring alongside fetal heart rate monitoring during labor significantly decreases the incidence of neonatal encephalopathy and severe neonatal acidemia.
